{"nctId":"NCT00296335","briefTitle":"Trial of Adjuvant Chemotherapy for Gastric Cancer","startDateStruct":{"date":"2002-02"},"conditions":["Stomach Cancer"],"count":855,"armGroups":[{"label":"Mitomycin and doxifluridine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Mitomycin and doxifluridine"]},{"label":"Mitomycin, doxifluridine and cisplatin","type":"EXPERIMENTAL","interventionNames":["Drug: Mitomycin, doxifluridine and cisplatin"]}],"interventions":[{"name":"Mitomycin, doxifluridine and cisplatin","otherNames":[]},{"name":"Mitomycin and doxifluridine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pathologically proven gastric adenocarcinoma\n* Curative resection was done\n* stage II, IIIA, IIIB, IV (including T4, lesions or N3, but excluding M1 lymph node metastasis)\n* age: 18-69 years old\n* Performance status: ECOG 0-2\n* Adequate bone marrow function (WBC ≥ 4,000/ul, platelet count ≥ 100,000/ul, hemoglobin ≥ 10 g/dl)\n* Adequate renal function (serum creatinine≤ 1.5)\n* Adequate liver function (serum bilirubin ≤1.5 mg/dl, AST/ALT ≤ 3 x normal upper limit)\n* Written informed consent was signed by the patient\n\nExclusion Criteria:\n\n* Previous chemotherapy or radiotherapy\n* Active ongoing infection which antibiotic treatment is needed\n* Pregnant or lactating women\n* Psychosis or convulsion disorder\n* Ascites in preoperative abdomen CT\n* Systemic disease which interfere the administration of chemotherapy\n* Previous history of other malignancy except cured non-malignant skin cancer and uterine cervical cancer in situ","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"69 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Relapse-free Survival Rate","description":"Relapse-free survival at 3 years was defined as the proportion of patients who did not show an evidence of disease recurrence after 3 years of surgery.\n\nRelapse was defined as any new tumor lesion.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.0","spread":null},{"groupId":"OG001","value":"64.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival Rate","description":"Overall survival rate at 3 years was defined as the proportion of patients who were alive at 3 years after surgery.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.9","spread":null},{"groupId":"OG001","value":"73.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Adverse Events","description":"Per National Cancer Institute Common Toxicity Criteria version 2.0, up to 3 years","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"262","spread":null},{"groupId":"OG001","value":"387","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"393","spread":null},{"groupId":"OG001","value":"413","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":null},{"groupId":"OG001","value":"156","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"343","spread":null},{"groupId":"OG001","value":"391","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"219","spread":null},{"groupId":"OG001","value":"288","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"293","spread":null},{"groupId":"OG001","value":"371","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"160","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":422},"commonTop":["Anemia","Fatigue","Anorexia","Nausea","Neutropenia"]}}}